Abbvie Inc

NYSE:ABBV   12:32:49 PM EDT
108.34
-1.15 (-1.05%)
Products

AbbVie Says FDA Approves Qulipta, Developed For Preventive Treatment Of Migraine

Published: 09/28/2021 23:06 GMT
Abbvie Inc (ABBV) - FDA Approves Qulipta™ (atogepant), the First and Only Oral Cgrp Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine.
Abbvie - Qulipta Demonstrated Statistically Significant, Clinically Meaningful Rapid, Continuous Reductions in Mean Monthly Migraine Days in Adults.
Abbvie Inc - Trial Showed When Taking Qulipta, Majority of Patients Experienced Between a 50-100% Reduction in Monthly Migraine Days Across 12 Weeks.